glp 1 fgf21 agonist boehringer Frontiers Management of type 2 diabetes,
Description
these drugs include glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors [13, 14]
Resistance training preserves and builds lean tissue during GLP-1 treatment by creating mechanical tension and protein synthesis stimulus that counteracts the medication's appetite suppression and modest lean mass reduction
Irwin N, McClean PL, OHarte FP, Gault VA, Harriott P, Flatt PR
Whats the bottom line on this issue, scientifically
Endocrinology Advisor Conclusion The 2025 GLP-1 guidelines reflect a paradigm shift in the management of type 2 diabetes, emphasizing the multifaceted benefits of these agents
The underlying mechanisms linking PsA to diabetes are complex and not yet fully understood[39]
